Update on the 2016 Aggressive Pituitary Tumour survey
In 2016 ESE developed a survey on aggressive pituitary tumours and carcinomas, the data that was generated from 167 patients was published in the European Journal of Endocrinology in 2018 (McCormack A, Dekkers OM, Petersenn S, Popovic V, Trouillas J, Raverot G, Burman P; ESE survey collaborators. Eur J Endocrinol. 2018; 178:265-276). All those who contributed with information on their patients were detailed as co-authors.
This survey provided new data on treatment, especially with temozolomide, and formed the basis for development of the ESE guidelines on aggressive pituitary tumours/pituitary carcinomas (Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, Trouillas J, Dekkers OM Eur J Endocrinol. 2018;178:G1-G24).
During this process several unanswered questions regarding diagnostics and management were identified. To address these, ESE would like to invite the clinicians who submitted patients into the 2016 survey to complete a second survey, “A European Survey for clinical diagnosis and management of Aggressive Pituitary Tumours and Pituitary Carcinomas”.